Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.
Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days. Passive stretch responses were measured before administration and for four hours afterwards. DS103-282 was more effective than baclofen, and both drugs were more effective than placebo. Analysis of the recordings confirmed that DS103-282 had a specific effect upon stretch reflexes independent of its effect on resting muscle tone. Its action appeared at 30 to 45 minutes after ingestion, with maximum activity at 60-90 minutes. Unwanted effects of DS103-282 were drowsiness and (in one case) potentiation of antihypertensive therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001418:Baclofen / Q000627:therapeutic use*; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D004576:Electromyography; D005260:Female; D006429:Hemiplegia / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy; D009128:Muscle Spasticity / Q000175:diagnosis / Q000188:drug therapy*; D010243:Paralysis / Q000188:drug therapy; D010919:Placebos
D010919:Placebos; C023754:tizanidine; D001418:Baclofen; D003000:Clonidine